Product is expected to maintain a steady temperature setting between 65°F (18°C) and 80°F (27°C).
Polar Leasing Company, Inc. (PLC), a provider of rental cold storage solutions for the pharma industry, has launched its validated Model A820 Ambient Temperature Walk-In Unit. This unit is designed to accommodate the storage requirement of pharma and life science products that demand a stable ambient (room temperature) environment.
The Model A820 is a ground-resting, electric-powered outdoor model developed to maintain a consistent temperature setting between 65°F (18°C) and 80°F (27°C), independent of external weather conditions. This NSF-approved ambient temperature solution is expected to bring substantial cost savings by eliminating the need for refrigeration and reducing energy consumption, maintenance, and infrastructure expenses.
Bart Tippmann, president of Polar Leasing, notes that while the technology differs from the traditional cold storage designs that customers may come to expect, the company's goals to quality remain the same, explaining that "every Polar Leasing unit, including these state-of-the-art ambient temperature solutions, adheres to the same high-quality standards."
LogiPharma Unpacked: Highlights, Key Insights, and the Road to 2025
October 16th 2024In this special post-show episode, we sit down with Ryan Portela, Head of Production for LogiPharma, to reflect on the highlights and key takeaways from this year’s event. From attendee feedback to the most impactful sessions, Ryan shares insider insights and discusses how the momentum from 2024 will continue to shape the future of pharma supply chains. Plus, get a sneak peek into the exciting plans for LogiPharma's 20th Anniversary in 2025.
Boosting Patient Adherence: The Power of Clinical Support Programs
October 3rd 2024In this podcast, we speak with Amanda Scholz, UBC Senior Clinical Program Manager, MHA, BSN, RN as we discuss the important role that clinical adherence programs play in empowering patients and bolster persistence to prescribed life-changing medications throughout their journey.